*/
© Shutterstock
Marie Law, Director of Toxicology at AlphaBiolabs, examines the latest ONS data on drug misuse and its implications for toxicology testing in family law cases
Substance misuse continues to play a significant role in family law proceedings, influencing decisions around safeguarding, parenting capacity and contact arrangements.
The latest Office for National Statistics (ONS) data confirms that drug use remains widespread, with millions of adults reporting recent use.
Although overall prevalence has remained broadly stable, the scale of misuse and changing profile of substances involved continue to present challenges for courts, reinforcing the need for proportionate, evidence-based drug testing in family proceedings.
The latest ONS figures underline the continued prevalence of drug misuse across England and Wales.
For the year ending March 2025:
While these levels have not increased markedly, they have also failed to decline, indicating that drug misuse remains a persistent issue.
For family courts, this translates into a steady flow of cases where historic or ongoing drug use must be carefully assessed.
The ONS data also challenges long-standing assumptions about who is most likely to misuse drugs. While younger adults continue to report the highest levels of use, there have been increases among older age groups (eg aged 45-54).
This shift is significant for family law, where substance misuse may arise in cases involving older parents or carers.
Socio-economic trends further complicate the picture, with higher rates of Class A drug use reported among higher-income households, undermining assumptions that serious drug misuse is confined to economically deprived groups.
For legal practitioners, these findings reinforce the importance of avoiding assumptions based on age, income or lifestyle. Instead, objective, court-admissible drug testing remains essential to accurately assess risk and safeguarding concerns.
Established substances continue to dominate patterns of misuse.
However, prevalence data alone does not fully reflect the complexity encountered in family law cases. In practice, courts are increasingly dealing with misuse of controlled prescription medications, new psychoactive substances and poly-drug combinations, many of which are not routinely included in standard testing panels.
This is particularly relevant where substances are taken without full awareness of their composition, or where prescribed drugs are misused, complicating disclosure and risk assessment.
Reliance on standard testing panels alone no longer provides a sufficiently accurate picture of an individual’s substance use, particularly where non-standard drugs or poly-drug use are involved.
In family proceedings, a narrow testing scope may fail to identify habitual or problematic use outside standard panels.
Additionally, symptoms of drug use often overlap across different substances, meaning that symptoms alone cannot be used to determine which drugs to test for.
Drug misuse remains a persistent feature of life in England and Wales, with patterns of use that are broad and increasingly complex. As drug use diversifies, testing strategies must evolve accordingly.
Substance misuse continues to play a significant role in family law proceedings, influencing decisions around safeguarding, parenting capacity and contact arrangements.
The latest Office for National Statistics (ONS) data confirms that drug use remains widespread, with millions of adults reporting recent use.
Although overall prevalence has remained broadly stable, the scale of misuse and changing profile of substances involved continue to present challenges for courts, reinforcing the need for proportionate, evidence-based drug testing in family proceedings.
The latest ONS figures underline the continued prevalence of drug misuse across England and Wales.
For the year ending March 2025:
While these levels have not increased markedly, they have also failed to decline, indicating that drug misuse remains a persistent issue.
For family courts, this translates into a steady flow of cases where historic or ongoing drug use must be carefully assessed.
The ONS data also challenges long-standing assumptions about who is most likely to misuse drugs. While younger adults continue to report the highest levels of use, there have been increases among older age groups (eg aged 45-54).
This shift is significant for family law, where substance misuse may arise in cases involving older parents or carers.
Socio-economic trends further complicate the picture, with higher rates of Class A drug use reported among higher-income households, undermining assumptions that serious drug misuse is confined to economically deprived groups.
For legal practitioners, these findings reinforce the importance of avoiding assumptions based on age, income or lifestyle. Instead, objective, court-admissible drug testing remains essential to accurately assess risk and safeguarding concerns.
Established substances continue to dominate patterns of misuse.
However, prevalence data alone does not fully reflect the complexity encountered in family law cases. In practice, courts are increasingly dealing with misuse of controlled prescription medications, new psychoactive substances and poly-drug combinations, many of which are not routinely included in standard testing panels.
This is particularly relevant where substances are taken without full awareness of their composition, or where prescribed drugs are misused, complicating disclosure and risk assessment.
Reliance on standard testing panels alone no longer provides a sufficiently accurate picture of an individual’s substance use, particularly where non-standard drugs or poly-drug use are involved.
In family proceedings, a narrow testing scope may fail to identify habitual or problematic use outside standard panels.
Additionally, symptoms of drug use often overlap across different substances, meaning that symptoms alone cannot be used to determine which drugs to test for.
Drug misuse remains a persistent feature of life in England and Wales, with patterns of use that are broad and increasingly complex. As drug use diversifies, testing strategies must evolve accordingly.
Marie Law, Director of Toxicology at AlphaBiolabs, examines the latest ONS data on drug misuse and its implications for toxicology testing in family law cases
The Chair of the Bar reports back
Susie Griffin on the admin that keeps barristers from billable work
Clement Cowley, Partner at The Penny Group, explains how global events can influence the performance of pensions and ISAs, and why taking a long-term approach to investing is often the most effective strategy
Mário Barroso, Head of R&D and Method Development at AlphaBiolabs, discusses what family law professionals need to know about hallucinogens, from the main hallucinogenic drugs encountered in family proceedings, to their effects and the testing options available
Harmony Christian Ministries is the latest charity to benefit from a £500 donation from AlphaBiolabs via the company’s Giving Back initiative
By David Green
The golden age of advocacy? David Langwallner pays homage to the filmic if contentious barrister Sir Edward Carson and some of his contemporaries
Leah Arthur, a pupil, and her second seat supervisor, John Goss, share their perspectives on building a productive pupil-supervisor relationship
Henry Fingerhut outlines what the Bar Standards Board AI guidance means for early career barristers
The Ministry of Justice will match-fund up to 100 criminal pupillages, with grants available to criminal chambers across England and Wales. Similar to the COIC scheme, the grants will match-fund pupillages additional to those otherwise offered without government funding
Not yet, says Jacob Turner. Regulation, unlike the technology itself, is a domain the legal profession can still control
